Abivax SA (ABVX) vs Axsome Therapeutics (AXSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed Abivax SA (ABVX) over the past year, gaining 45.8% versus a gain of 0.0%. Axsome Therapeutics is the larger company by market cap ($8.85 billion vs $7.46 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | AXSM |
|---|---|---|
| Share price | $85.50 | $168.92 |
| Market cap | $7.46B | $8.85B |
| 1-day change | -1.74% | -2.34% |
| YTD return | -35.48% | -5.29% |
| 1-year return | 0.00% | +45.79% |
| 5-year return | — | +331.35% |
| Forward P/E | — | 35.80 |
| EPS (TTM) | $-6.08 | $-3.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $638.50M |
| Revenue growth (YoY) | — | +65.55% |
| Net income (latest FY) | — | $-183.17M |
| Gross margin | — | 92.56% |
| Operating margin | — | -26.12% |
| Net margin | — | -28.69% |
| 52-week high | $148.83 | $260.19 |
| 52-week low | $69.81 | $118.71 |
| Distance from 52-week high | -42.56% | -35.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +91.82% | +68.50% |
| Average volume | 1.10M | 705.24K |
| Shares outstanding | 87.27M | 52.38M |
| Employees | 98 | 1,346 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXSM has outperformed ABVX by 45.8 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
ABVX vs AXSM FAQ
Which is bigger, Abivax SA or Axsome Therapeutics?
Axsome Therapeutics (AXSM) is larger, with a market capitalization of $8.85B compared with $7.46B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or AXSM?
AXSM returned +45.79% over the past 12 months, compared with 0.00% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Axsome Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.